Published in Diabetes Care on May 01, 2013
Atrial natriuretic peptide genetic variant rs5065 and risk for cardiovascular disease in the general community: a 9-year follow-up study. Hypertension (2013) 1.02
Atrial natriuretic peptide in cardiovascular biology and disease (NPPA). Gene (2015) 0.84
Natriuretic Peptides and Cardiometabolic Health. Circ J (2015) 0.79
cGMP: transition from bench to bedside: a report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.79
Genetic and nongenetic factors influencing pharmacokinetics of B-type natriuretic peptide. J Card Fail (2014) 0.77
Atrial natriuretic peptide and type 2 diabetes development--biomarker and genotype association study. PLoS One (2014) 0.75
INTERACTING DISCIPLINES: Cardiac natriuretic peptides and obesity: perspectives from an endocrinologist and a cardiologist. Endocr Connect (2015) 0.75
The Anp genetic variant Rs5068 and circulating levels of natriuretic peptides in patients with chronic heart failure. Int J Cardiol (2014) 0.75
Divergent effects of a designer natriuretic peptide CD-NP in the regulation of adipose tissue and metabolism. Mol Metab (2017) 0.75
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem (1972) 95.79
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation (2002) 76.93
The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med (1997) 19.14
Impact of obesity on plasma natriuretic peptide levels. Circulation (2004) 4.46
Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest (2012) 4.01
Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet (2009) 3.81
The National Survey of Stroke. Clinical findings. Stroke (1981) 3.45
Gene structure of human cardiac hormone precursor, pronatriodilatin. Nature (1985) 2.41
Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J (2000) 2.24
Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes (2009) 2.03
Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation (2007) 1.93
Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol (1984) 1.71
Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol (2012) 1.66
Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J Biol Chem (2003) 1.62
Lipolytic effects of B-type natriuretic peptide 1-32 in adipose tissue of heart failure patients compared with healthy controls. J Am Coll Cardiol (2011) 1.59
Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab (2011) 1.50
Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest (1996) 1.39
Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab (2005) 1.32
Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. J Hypertens (1997) 1.26
A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. J Am Coll Cardiol (2011) 1.20
Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes. J Mol Cell Cardiol (2011) 1.17
The natriuretic peptides and fat metabolism. N Engl J Med (2012) 1.04
The lipid-mobilizing effect of atrial natriuretic peptide is unrelated to sympathetic nervous system activation or obesity in young men. J Lipid Res (2001) 1.01
Comparative analysis of atrial natriuretic peptide receptor expression in rat tissues. J Hypertens Suppl (1993) 0.97
A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower atrial natriuretic peptide and higher blood pressure in obese hypertensives. J Hypertens (1999) 0.96
A review of the role of atrial natriuretic peptide gene polymorphisms in hypertension and its sequelae. Curr Hypertens Rep (2009) 0.96
Natriuretic peptide clearance receptor alleles and susceptibility to abdominal adiposity. Obes Res (2004) 0.94
Fasting inhibits natriuretic peptides clearance receptor expression in rat adipose tissue. J Hypertens (1995) 0.92
Atrial natriuretic peptide contribution to lipid mobilization and utilization during head-down bed rest in humans. Am J Physiol Regul Integr Comp Physiol (2007) 0.87
Chronic hypertension in ANP knockout mice: contribution of peripheral resistance. Regul Pept (1999) 0.86
Hemodynamics in transgenic mice with overexpression of atrial natriuretic factor. Circ Res (1994) 0.84
Prevalence of overweight and obesity in a rural southern Italy population and relationships with total and cardiovascular mortality: the Ventimiglia di Sicilia project. Int J Obes Relat Metab Disord (2001) 0.81
Hypertension and diabetes mellitus are associated with cardiovascular events in the elderly without cardiovascular disease. Results of a 15-year follow-up in a Mediterranean population. Nutr Metab Cardiovasc Dis (2008) 0.80
Association of common variants in NPPA and NPPB with blood pressure does not translate into kidney damage in a general population study. J Hypertens (2010) 0.78
Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA (2003) 13.79
Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation (2006) 11.78
Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature (2002) 10.96
Burden of valvular heart diseases: a population-based study. Lancet (2006) 8.94
The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol (2004) 8.21
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25
Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer (2008) 6.10
Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med (2005) 5.94
S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science (2006) 5.94
Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell (2005) 5.71
Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev (2004) 4.68
Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol (2002) 4.56
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA (2007) 4.30
The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint. Cell (2008) 4.04
Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature (2004) 3.73
Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol (2002) 3.68
Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J Biol Chem (2003) 3.68
Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo. Dev Cell (2003) 3.62
SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins. Science (2007) 3.59
Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature (2003) 3.54
PCNA-dependent regulation of p21 ubiquitylation and degradation via the CRL4Cdt2 ubiquitin ligase complex. Genes Dev (2008) 3.49
Natural history of asymptomatic mitral valve prolapse in the community. Circulation (2002) 3.40
Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest (2002) 3.36
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA (2008) 3.31
E2-2 protein and Fuchs's corneal dystrophy. N Engl J Med (2010) 3.31
Degradation of Id2 by the anaphase-promoting complex couples cell cycle exit and axonal growth. Nature (2006) 3.31
Outcomes after aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function. Circulation (2002) 3.25
Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography. J Am Coll Cardiol (2003) 3.20
Left atrial volume: a powerful predictor of survival after acute myocardial infarction. Circulation (2003) 3.08
The after-hours mutant reveals a role for Fbxl3 in determining mammalian circadian period. Science (2007) 3.05
American Idol and NIH Grant Review. Cell (2006) 3.01
Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA (2011) 2.86
Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension (2012) 2.86
Flow-gradient patterns in severe aortic stenosis with preserved ejection fraction: clinical characteristics and predictors of survival. Circulation (2013) 2.83
Mammographic breast density as a general marker of breast cancer risk. Cancer Epidemiol Biomarkers Prev (2007) 2.81
Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension (2007) 2.77
SCFbetaTrCP-mediated degradation of Claspin regulates recovery from the DNA replication checkpoint response. Mol Cell (2006) 2.75
Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase. Mol Cell (2005) 2.75
Left atrial volume as an index of left atrial size: a population-based study. J Am Coll Cardiol (2003) 2.62
Mechanisms and function of substrate recruitment by F-box proteins. Nat Rev Mol Cell Biol (2013) 2.56
Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter? J Am Coll Cardiol (2006) 2.55
Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation. Cell (2003) 2.54
Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res (2002) 2.51
Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol (2002) 2.50
Control of chromosome stability by the beta-TrCP-REST-Mad2 axis. Nature (2008) 2.46
Left atrial volume predicts cardiovascular events in patients originally diagnosed with lone atrial fibrillation: three-decade follow-up. Eur Heart J (2005) 2.45
Association of ambulatory blood pressure with ischemic brain injury. Hypertension (2007) 2.39
Limitations of estimating glomerular filtration rate from serum creatinine in the general population. Mayo Clin Proc (2006) 2.37
The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol (2010) 2.37
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol (2008) 2.35
APC/C(Cdc20) controls the ubiquitin-mediated degradation of p21 in prometaphase. Mol Cell (2007) 2.35
Specific small molecule inhibitors of Skp2-mediated p27 degradation. Chem Biol (2012) 2.34
For estimating creatinine clearance measuring muscle mass gives better results than those based on demographics. Kidney Int (2009) 2.32
The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein. Nat Cell Biol (2008) 2.32
Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol (2007) 2.32
Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol (2003) 2.27
Survival in patients with poorly compressible leg arteries. J Am Coll Cardiol (2012) 2.25
A critique on contemporary reporting of likelihood ratios in test power analysis. Mayo Clin Proc (2004) 2.23
JHDM1B/FBXL10 is a nucleolar protein that represses transcription of ribosomal RNA genes. Nature (2007) 2.20
Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation (2005) 2.20
The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol (2003) 2.19
Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratification in primary systematic (AL) amyloidosis: a 5-year cohort study. Eur Heart J Cardiovasc Imaging (2012) 2.16
SCF(Cyclin F) controls centrosome homeostasis and mitotic fidelity through CP110 degradation. Nature (2010) 2.15
Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N Engl J Med (2008) 2.14
Measurement and quality control issues in multiplex protein assays: a case study. Clin Chem (2009) 2.11
Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: clinical profile, practice patterns, and outcomes spanning 21 years. Mayo Clin Proc (2002) 2.08
Rac1 accumulates in the nucleus during the G2 phase of the cell cycle and promotes cell division. J Cell Biol (2008) 2.08
Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome. Proc Natl Acad Sci U S A (2004) 2.05
Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol (2008) 2.04
Leptin deficiency promotes central sleep apnea in patients with heart failure. Chest (2014) 1.99
Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol (2006) 1.98
Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell (2012) 1.98
Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades. Eur Heart J (2006) 1.97
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
Dual mode of degradation of Cdc25 A phosphatase. EMBO J (2002) 1.95
Antibody-based protein multiplex platforms: technical and operational challenges. Clin Chem (2009) 1.95
APC/C- and Mad2-mediated degradation of Cdc20 during spindle checkpoint activation. Cell Cycle (2009) 1.94
USP33 regulates centrosome biogenesis via deubiquitination of the centriolar protein CP110. Nature (2013) 1.94
KDM2A represses transcription of centromeric satellite repeats and maintains the heterochromatic state. Cell Cycle (2008) 1.90
Longitudinal trends in mammographic percent density and breast cancer risk. Cancer Epidemiol Biomarkers Prev (2007) 1.90
Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens (2010) 1.90
Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. J Card Fail (2008) 1.89
Comparison of natural language processing biosurveillance methods for identifying influenza from encounter notes. Ann Intern Med (2012) 1.89
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J (2011) 1.88
Left atrial volume predicts the risk of atrial fibrillation after cardiac surgery: a prospective study. J Am Coll Cardiol (2006) 1.88
SnapShot: F Box Proteins II. Cell (2009) 1.88
Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med (2007) 1.88
Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A (2005) 1.85
Severe pulmonary hypertension in patients with severe aortic valve stenosis: clinical profile and prognostic implications. J Am Coll Cardiol (2002) 1.85
Novel p27(kip1) C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. Mol Cell Biol (2003) 1.85
Usefulness of left atrial volume in predicting first congestive heart failure in patients > or = 65 years of age with well-preserved left ventricular systolic function. Am J Cardiol (2005) 1.84
Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension (2007) 1.84
Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation (2004) 1.82
FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature (2012) 1.79
Pro-B-type natriuretic peptide(1-108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction. J Am Coll Cardiol (2011) 1.78